Contineum Therapeutics (CTNM) Shares Outstanding (Weighted Average) (2023 - 2026)

Contineum Therapeutics' Shares Outstanding (Weighted Average) history runs 4 years deep, the most recent figure standing at $37.3 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 44.34% year-over-year to $37.3 million; the TTM figure through Mar 2026 stood at $37.3 million (up 44.34% YoY), while the FY2025 annual figure was $27.7 million, up 43.14% from the prior year.
• Shares Outstanding (Weighted Average) was $37.3 million for Q1 2026 at Contineum Therapeutics, up from $27.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $37.3 million in Q1 2026 to a low of $2.3 million in Q1 2023.
• Historically, Shares Outstanding (Weighted Average) has averaged $16.6 million across 4 years, with a median of $19.4 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) grew 4.02% in 2024, then jumped 991.95% in 2025.
• A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $2.3 million in 2023, then surged by 738.16% to $19.4 million in 2024, then surged by 43.14% to $27.7 million in 2025, then surged by 34.79% to $37.3 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $37.3 million (Q1 2026), $27.7 million (Q4 2025), and $28.1 million (Q3 2025), per Business Quant data.